Adverts

Open Access Articles- Top Results for Buflomedil

Buflomedil

Buflomedil
200px
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Names

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

IUPAC name
4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Identifiers#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-


ATC code C04AX20
55837-25-7 7pxY
ChEMBL ChEMBL188921 7pxY
ChemSpider 2373 7pxY
Jmol-3D images Image
PubChem Template:Chembox PubChem/format
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Properties

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

C17H25NO4
Molar mass 307.38 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 14pxY verify (what is10pxY/10pxN?)
Infobox references

Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States. Currently available as trade name tablet Loftyl

Toxicity

This drug might be suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity.[1][2] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options".

Various adverse effects have been reported to the FDA.[3]

References

Lua error in package.lua at line 80: module 'Module:Buffer' not found.